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Abstract
We report a method to enrich cysteinyl adducts of human serum albumin (HSA)2, representing
biomarkers of exposure to systemic electrophiles. Because the major site of HSA adduction is the
single free sulfhydryl group at Cys34, we used thiol-affinity resins to remove mercaptalbumin (i.e.,
unadducted HSA) from the cysteinyl adducts. Electrospray ionization mass spectrometry was used
to detect mercaptalbumin and HSA-Cys34 modifications before and after enrichment of HSA.
Differences in adduct content were detected across samples of freshly-isolated, archived, and
commercial HSA. Cysteinylated and glycosylated adducts were present in all samples with
abundances decreasing in the order: commercial HSA > archived HSA > fresh HSA. After enrichment
of HSA, mercaptalbumin was no longer observed in mass spectra. The ratio of HSA adducts post-/
pre-enrichment, quantified via the Bradford assay and gel electrophoresis, was 0.029 mg adducts/
mg HSA in fresh HSA and 0.323 mg adducts/mg HSA in archived HSA. The apparent elevation of
adduct levels in archived samples could be due to differences in specimen preparation and storage,
rather than to differences in circulating HSA adducts. We conclude that thiol-affinity resins can
efficiently remove mercaptalbumin from HSA samples prior to characterization and quantitation of
protein adducts of reactive systemic electrophiles.
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It has been argued that biomarkers of exposure should be used in studies of the effects of toxic
chemicals on human health [1]. Biomarkers can also provide a more precise estimate of internal
dose, which increases the power to detect relationships between adverse health effects and
causal agents [2]. However, because environmental toxicants are often chemically reactive
electrophiles, their short life spans in vivo make them difficult to measure directly in biological
media. This has motivated the use of stable adducts of these electrophiles with abundant blood
proteins, notably hemoglobin and human serum albumin (HSA), as exposure biomarkers
(reviewed by Tornqvist et al., [3] and Rubino et al., [4]). Stable adducts accumulate over the
mean residence time of a protein and thereby reflect the integral of the blood level of the reactive
species over, for example, 28 d for human serum albumin (HSA) and 60 d for hemoglobin.
This makes protein adducts potentially more useful measures of exposure for retrospective
epidemiologic studies than environmental measurements or short-term biomarkers, such as
urinary metabolites or blood levels of parent compounds, which have residence times of hours
or days [2].
Human serum albumin contains 35 cysteine residues, 34 of which are bound as intramolecular
disulfides. Although the remaining cysteine, Cys34, has the only free sulfhydryl group in HSA,
it represents the largest fraction of thiols in serum [5], where it has been estimated to account
for approximately 80% of the antioxidant capacity [6;7]. Within the tertiary protein structure
of HSA, Cys34 resides in a unique microenvironment close to three ionizable residues:
Asp38, His39, and Tyr84 [8]. As a result, Cys34 has an unusually low pKa (<6.7 compared to
about 8.0 - 8.5 for thiols in most other proteins and peptides) and exists primarily in the highly
nucleophilic thiolate form [8]. Examples of the many chemical species that form adducts with
Cys34 include oxirane and quinone metabolites of benzene, naphthalene, and
pentachlorophenol [9;10;11;12;13], nitrogen mustards [14], 4-hydroxy-trans-2-nonenal, 2-
propenal, malondialdehyde, glyoxal, and other products of lipid peroxidation [15;16;17], metal
ions such as Ag+, Hg2+, and Au+, and a host of drugs including auranofin, D-penicillamine,
ethacrynate, and cisplatin (reviewed by [18]). Yet, although some HSA-Cys34 adducts have
been detected in studies of humans, the analytical matrix is complex and the levels of individual
adducts have been very low (less than one in a million unadducted protein molecules [4]). The
combination of matrix effects plus low abundance has made it difficult to simultaneously
measure numerous HSA adducts in samples of human serum or plasma and to identify unknown
adducts.
Here we report a method to selectively enrich Cys34 adducts in fresh or archived samples of
HSA. The enrichment approach takes advantage of the propensity of HSA containing
unmodified Cys34 (mercaptalbumin) to bind with thiol-affinity resins [19]. Because adducted
HSA is comprised primarily of small mixed-disulfides that exhibit reversible binding with
HSA-Cys34, disulfide adducts were reduced to mercaptalbumin by dithiothreitol (DTT) prior
to treatment with thiol-affinity resins. Using electrospray ionization (ESI) mass spectrometry,
we characterized intact HSA from various sources and investigated the effects of reduction of
mixed disulfides on the enrichment process. Enrichment was assessed both by mass
spectrometry of the intact proteins and also by quantifying the amounts of HSA via the Bradford
assay and gel electrophoresis before and after enrichment via thiol-affinity resins.
MATERIALS AND METHODS
Chemicals
Dithiothreitol (DTT), tris(2-carboxyethyl)phosphine (TCEP), iodoacetamide (IAA),
phosphate buffered saline, Activated Thiol Sepharose 4B, sequence grade trypsin, sodium
chloride, calcium chloride, ammonium sulfate, nitrogen, BioRad reagent dye, sodium dodecyl
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sulfate, BioSafe Coomassie G-250 dye (Bio-Rad, Hercules, CA), ammonium sulfate, Tris base,
ProteasMAX, acetonitrile (Fisher Optima grade, 99.9%) and formic acid (Pierce, 1 ml
ampoules, 99+%) were purchased from Fisher Scientific (Pittsburgh, PA). Commercial HSA
was from Sigma (St. Louis, MO). Water was purified to a resistivity of 18.2 MΩ·cm (at 25 °
C) using a Milli-Q Gradient ultrapure water purification system (Millipore, Billerica, MA).
Isolation of HSA
Four ml of whole blood were obtained from a healthy Asian volunteer subject (age = 34 y) by
venipuncture in heparin. The blood was immediately centrifuged for 15 minutes at 3000 × g.
The plasma layer was transferred to a 15-ml centrifuge tube, and saturated ammonium sulfate
was added drop-wise to a final concentration of 60% ammonium sulfate. The plasma was
vortexed briefly and centrifuged for 30 minutes at 3000 × g to pellet the precipitated protein.
The supernatant, containing HSA, was transferred to 10-kDa molecular weight cutoff (MWCO)
spin columns (Amicon Ultra-4, Millipore, Billerica, MA) and the protein was desalted using
5 x 15-ml volumes of deionized water. The isolated HSA was immediately aliquoted and frozen
at -80°C. Archived HSA from 40 volunteer subjects (pooled and balanced from males/females,
smokers/nonsmokers, and black/white subjects; 5 subjects per pool) had previously been
isolated according to a similar protocol [20], which included dialysis to remove small
molecules, lyophilization to constant weight, and dissolving the purified HSA in deionized
water at 50 mg/ml. Archived samples were stored at -80°C prior to processing in the current
study.
Mass Spectrometry of HSA
The heterogeneity of HSA with respect to Cys34-adduct status was evaluated in freshly isolated
and archived HSA (described above), and commercial HSA from Sigma-Aldrich. Protein
samples were analyzed using an Agilent 1200 series liquid chromatograph (LC; Santa Clara,
CA) that was connected in-line with an LTQ Orbitrap XL hybrid mass spectrometer equipped
with an Ion Max electrospray ionization (ESI) source (Thermo Fisher Scientific, Waltham,
MA). The LC was equipped with C8 guard (Poroshell 300SB-C8, 5 μm, 12.5 × 2.1-mm,
Agilent) and analytical (75 × 0.5-mm) columns and a 100-μl sample loop. Solvent A was 0.1%
formic acid/99.9% water and solvent B was 0.1% formic acid/99.9% acetonitrile (v/v). For
each sample, approximately 50 to 100 pmol of protein analyte was injected onto the column
using an Agilent 1200 autosampler. Following sample injection, analyte trapping was
performed for 5 min with 99.5% A at a flow rate of 90 3μ/min. The elution program consisted
of a linear gradient from 25% to 95% B over 34 min, isocratic conditions at 95% B for 5 min,
a linear gradient to 0.5% B over 1 min, and then isocratic conditions at 0.5% B for 14 min, at
a flow rate of 90 μl/min. The column and sample compartments were maintained at 35 °C and
10 °C, respectively. Solvent (Milli-Q water) blanks were run between samples, and the
autosampler injection needle was rinsed with Milli-Q water after each sample injection, to
avoid cross-contamination between samples. The mass spectrometer ESI source parameters
were as follows: ion transfer capillary temperature 275 °C, normalized sheath gas (nitrogen)
flow rate 25%, ESI voltage 2.0 kV, ion transfer capillary voltage 33 V, and tube lens voltage
125 V. Positive-ion mass spectra were recorded over the range m/z = 500 to 2000 using the
Orbitrap mass analyzer, in profile format, with full MS automatic gain control target settings
of 3×104 and 5×105 charges for the linear ion trap and the Orbitrap, respectively, and an
Orbitrap resolution setting of 6×104 (at m/z = 400, FWHM). Raw mass spectra were processed
using Xcalibur software (version 4.1, Thermo) and measured charge state distributions were
deconvoluted using ProMass software (version 2.5 SR-1, Novatia, Monmouth Junction, NJ),
using the default “large protein” parameters and a background subtraction factor of 1.5.
Reproducibility of the measured masses of intact, adducted HSA proteins was within ± 3 Da
(calculated from the repetitive measurements of the deconvoluted mass spectra of HSA samples
over two weeks).
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Reduction of HSA Mixed Disulfides
The efficiency of reducing small mixed disulfides bound to HSA-Cys34 was investigated with
both DTT and TCEP. One-mg portions of commercial HSA were treated with one of 11
different concentrations of DTT or TCEP that ranged from equimolar to 270-fold molar excess,
with reaction times ranging from 5 to 60 minutes. All experiments were conducted at room
temperature in phosphate buffer, pH 7.4. Following protein reduction, samples were reacted
with iodoacetamide (IAA), and the degree of reduction was assessed by monitoring the number
of IAA additions (+57 Da per modification) above the measured mass of HSA (66,436±3 Da)
[21;22]. Reduction status was assessed before and after reduction using a LTQ Orbitrap XL
hybrid mass spectrometer under the same MS conditions described above. Reduction
conditions were considered optimal when they were stringent enough to reduce the Cys34-
mixed disulfides while also preserving the intramolecular disulfide linkages.
For enrichment experiments, 2-mg portions of fresh HSA (n = 6) and 0.5-mg portions of pooled
archived HSA (n = 16) were reduced using a 2.7-fold molar excess of DTT to release Cys34-
bound mixed disulfides in 1-ml and 0.5-ml volumes, respectively. This concentration of DTT
had been found to be optimal in preliminary experiments with commercial HSA (described
above).
Using IAA-modified HSA as a Positive Control
IAA was reacted with HSA to create a Cys34 adduct that would serve as a positive control for
the enrichment experiments. Commercial HSA was treated with a 2.7 molar excess of DTT
and was reacted with 150 mM IAA in phosphate buffer, pH 7.4, at 37°C for 1 h. After removing
excess IAA and buffer salts with a 10-kDa MWCO spin column, the fully-modified HSA was
diluted with freshly isolated HSA to produce a starting solution containing 0.047 mg of the
IAA-modified HSA per mg of HSA.
Using Thiol-affinity Resins to Remove Mercaptalbumin from HSA
A slurry containing a dry weight of either 250 mg (for fresh HSA) or 75 mg (for archived HSA)
of Activated Thiol Sepharose 4B hydrated resin in degassed 4B binding buffer (100 mM Tris-
HCl, 0.5 M NaCl, pH 7.4) was prepared in a ratio of 75% settled medium to 25% buffer. The
slurry was transferred to a 1.5-ml polypropylene spin tube containing cellulose acetate
membranes with a 0.22-μm pore size (Pierce Spin Cups, Thermo Scientific, Pittsburgh, PA).
The reduced HSA starting solution, containing either fresh or archived HSA was added to the
resin, mixed by vortexing, capped with nitrogen, and sealed with Parafilm®. After incubating
at room temperature for 16 h on a rotary suspension mixer, the unbound proteins were removed
from the thiol-affinity medium by centrifuging at 7000 rpm for 5 minutes. The flow-through
fraction containing the HSA-Cys34 adducts was recovered.
Quantitation of Total Proteins and HSA
Electron ionization mass spectrometry was used to detect mercaptalbumin and HSA-Cys34
modifications before and after treatment of HSA with thiol-affinity resins. The total amounts
of proteins in pre- and post-enrichment samples were determined in duplicate with the Bradford
assay according to the standard microtiter plate protocol from the manufacturer (Bio-Rad,
Hercules, CA) using commercial HSA for the standard curve. The purity of the isolated HSA
was determined by sodium dodecyl sulfate-polyacrylamide gel electrophoresis (SDS-PAGE).
Aliquots containing 10 μg of total protein in 10 μl of deionized water were mixed with 10 μl
of 2X Laemmli sample buffer (Bio-Rad, Hercules, CA) containing 10% SDS and 5% β-
mercaptoethanol and boiled for 10 min. The denatured samples and prestained molecular
weight markers (Precision-Plus Protein Standards, Bio-Rad) were loaded on 4 – 20%
polyacrylamide gradient gels (NuSep, Lawrenceville, GA) and separated at 100 V for one hour.
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The gels were stained with Bio-Safe Coomassie G-250 dye (Bio-Rad) and the relative
concentrations of the various protein bands were determined by densitometry using an
AlphaImager HP (Alpha Innotech, San Leandro, CA). The purity of HSA was expressed as
the percentage of the sum of all protein bands.
Estimation of HSA-Cys34 Adduct Levels in HSA Samples
The HSA content of samples before and after removal of mercaptalbumin by thiol-affinity
resins was quantified by measuring total proteins with the Bradford assay and gel
electrophoresis (described above). After removal of mercaptalbumin, the protein content of
post-enrichment samples reflected the quantity of adducted HSA-Cys34. Proportions of HSA
adducts were, therefore, estimated as ratios of mean quantities of HSA after thiol-affinity
treatment to those observed before treatment (mg adducts/mg HSA). For freshly-isolated HSA
that had been spiked with IAA-modified HSA (positive control), this ratio was adjusted by
subtracting the proportion of IAA adducts that had been added (0.047 mg IAA adducts/mg
HSA).
Statistical Analysis
Adduct levels (mg Adducts/mg HSA) in samples of enriched HSA from archived specimens
were analyzed with general linear models using Proc GLM of SAS (SAS for Windows v. 9.2,
Cary, NC). Dummy variables were assigned for race (white or black), gender, and smoking
status.
RESULTS AND DISCUSSION
Mass Spectrometry of HSA
Using LC-MS, we characterized intact HSA before and after enrichment of HSA-Cys34
adducts. The total ion chromatogram of freshly isolated HSA, given in Figure 1A, shows a
major peak (labeled as ‘HSA’) followed by smaller peaks, representing other plasma proteins
that were not precipitated by treatment with 60% ammonium sulfate. The raw ESI mass
spectrum of HSA (Figure 1B) exhibits charge states 34+ through 66+.
Heterogeneity of HSA
Human serum albumin is heterogeneous with respect to the thiol redox state, and exists in both
the reduced and oxidized forms. The degree of HSA oxidation in vivo has been reported to
increase with oxidative stress and various disease conditions, suggesting that HSA is an
important scavenger of reactive systemic oxidants [23;24]. However, after collection of blood
specimens, Cys34 can be further oxidized during sample storage and processing. In particular,
oxidation of Cys34 has been observed to initiate addition reactions with cysteine, and mixed
disulfides [21;24;25;26].
In this study, the degree of HSA-Cys34 modification was examined for three different HSA
preparations: freshly isolated HSA, archived HSA, and commercial HSA. As shown in Figure
2, ESI mass spectrometry of the intact proteins points to different adduct profiles for these three
sources of HSA. The spectrum of freshly isolated HSA (Figure 2A) was dominated by the mass
corresponding to mercaptalbumin (66,436 Da), with a few lower abundance masses also
observed, including one at 66,556 Da representing HSA+Cys (the cysteinylated product) and
another at 66,599 Da, corresponding to HSA+Gluc (the glycosylated product). [Since the
primary site for nonenzymatic glycosylation is Lys [27;28], glycosylation should not preclude
modifications of Cys34]. Commercial HSA contained the largest fraction of HSA+Cys, which
was twice as abundant as mercaptalbumin (Figure 2B). The ESI mass spectrum of commercial
HSA also showed less abundant masses at 66,473 Da, consistent with NO modification, and
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at 66,512 Da (modification unknown). In the archived HSA spectrum, mercaptalbumin was
the most abundant species (Figure 2C) and prominent peaks corresponding to cysteinylation
and glycosylation were observed at higher levels than in the fresh HSA sample.
Reduction of HSA-Cys34 Mixed Disulfides
As indicated above, the most abundant modification on HSA-Cys34 was cysteinylation.
Although cysteinylation was relatively minor in freshly isolated HSA (the 66,556 Da
component in Figure 2A), higher levels of cysteinylated HSA were observed in the archived
samples (66,556 Da; Figure 2C). As such, it is important to reduce HSA prior to treatment with
thiol-affinity resins to achieve maximum enrichment of non-disulfide adducts.
We explored the reduction of mixed thiol disulfides using either DTT or TCEP at room
temperature with 1-mg specimens of commercial HSA. Eleven different concentrations of DTT
or TCEP were tested that ranged from a molar equivalent of reducing agent to 270-fold molar
excess, with reaction times ranging from 5 to 60 minutes. The reaction time did not have a
significant effect in any of the experiments using either TCEP or DTT (data not shown). Mass
spectra from these experiments provide evidence that between two and five intramolecular
disulfides were cleaved, corresponding to 5 – 11 IAA modifications, respectively; indeed,
TCEP cleaved one intramolecular disulfide at the lowest (equimolar) concentration tested. In
contrast, no intramolecular disulfides were broken with DTT at concentrations between 2.7-
fold and 10.8-fold molar excess, indicating that Cys34 was the only cysteine residue reduced
under these conditions.
As illustrated in Figure 3A, incubation of commercial HSA with a 2.7-fold molar excess of
DTT effectively reduced Cys34-mixed disulfides, while preserving the intramolecular disulfide
linkages. The most intense peak in the deconvoluted ESI mass spectrum was at 66,493 Da,
corresponding to HSA with a single IAA modification. The mass in this spectrum at 66,654
Da is likely to be glycosylated HSA-Cys34-IAA while the minor peak at 66,559 Da is probably
glycosylated mercaptalbumin [21]. The latter suggests that a small fraction of mercaptalbumin
was not modified with IAA. The peak at 66,554 Da was also observed in spectra from HSA
that had not been treated with IAA and is, therefore, unlikely to represent an IAA modification
of HSA-Cys34. This peak (at 66,554 Da) could represent other covalent modifications of HSA-
Cys34 that were not reduced with a 2.7-fold molar excess of DTT.
At a 27-fold molar excess of DTT, commercial HSA was modified with two additional IAA
molecules, indicating one broken intramolecular disulfide. When DTT concentrations reached
270-fold excess, as shown in Figure 3B, a series of peaks was observed with masses close to
those expected for addition products representing 1 to 5 IAA molecules to HSA. The respective
observed and expected masses for these peaks, assuming a mass of 66,436 Da for free HSA,
were as follows: 66,493 Da (1 IAA: +57 Da observed and expected), 66,554 Da (2 IAA: +118
Da observed vs. 114 Da expected), 66,610 Da (3 IAA: +174 Da observed vs. 171 expected),
66,664 (4 IAA: +228 Da observed and expected), and 66,723 Da (5 IAA: +287 Da vs. 285 Da
expected). All of these observed masses are reasonable given our mass accuracy of ± 3 Da,
with the possible exception of the peak at 66,554 Da which corresponds to a mass also observed
without IAA treatment and, therefore, could represent a mixture of HSA with two IAA
additions plus unknown HSA-Cys34 adducts. Although the last major peak in the mass
spectrum, i.e., at 66,773 Da, could represent HSA with 6 IAA additions, the difference between
observed and expected masses (6 IAA: +337 Da observed vs. 342 Da expected) is larger than
our nominal mass accuracy.
Based on these results, a 2.7-fold molar excess of DTT was selected for reducing mixed
disulfides without disrupting the intramolecular disulfide bridges. Reactions were performed
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at room temperature for 5 minutes. These reduction conditions are consistent with previous
studies [29].
Qualitative Assessment of HSA-Cys34 Adduct Enrichment
Figure 4 shows the deconvoluted ESI mass spectra of HSA before and after enrichment of the
Cys34 adducts with thiol-affinity resins. Three prominent peaks were observed in the pre-
enrichment spectrum at 66,436, 66,556, and 66,599 Da, corresponding to HSA, HSA+Cys and
HSA+Gluc, respectively, consistent with previous findings [21;30]. After enrichment, three
abundant peaks were observed in the spectrum at 66,493, 66,545, and 66,705 Da. The first
peak at 66,493 (+57) Da corresponds to HSA-Cys34-IAA (positive control), which was not
resolved in the pre-enrichment spectrum, where the starting concentration of HSA-Cys34-IAA
was 0.047 mg/mg HSA. The most intense peak in the post-enrichment spectrum (Figure 4B)
was at 66,545 Da, which corresponds to a mass addition of 109 Da. In the three-dimensional
structure of HSA, the Cys34 residue resides in a cleft that is about 10 Å deep (He and Carter,
1992), which can sterically limit access to this residue by large electrophiles. It is therefore
reasonable to expect Cys34 adducts that are of limited mass, i.e., in the range of 109 Da.
A peak at 66,705 (66,545 + 160) Da was also observed in the post-enrichment spectrum. This
probably represents the corresponding pool of N-linked glycosylated HSA-Cys34 adducts.
Because all of the ions resolved in the post-enriched spectrum were adducted HSA-Cys34
species, it appears that treatment of HSA with thiol affinity resins effectively removed
mercaptalbumin.
Quantitative Assessment of HSA-Cys34 before and after Enrichment
The amount of HSA in each sample was calculated using the Bradford assay to measure total
protein, and SDS-PAGE to determine the purity of HSA. Gel-electrophoresis images are shown
pre- and post-enrichment in Figure 5. Before treatment with thiol-affinity resins, the fresh HSA
sample contained 70.6% HSA, and the archived HSA had a mean purity of 46.9% (SD 6.8).
After treatment, the mean purity was 67.6% (SD 4.0) and 68.4% (SD 9.7) for the fresh and
archived HSA, respectively. The archived HSA may have been altered during the isolation
process (where dialysis and lyophilization were used) or may have degraded over time (11 y
at -80°C), thus resulting in the observed lower HSA purity. Further work is needed to determine
the effects of HSA isolation and storage on levels of HSA-Cys34 adducts and also to confirm
adduct levels in fresh HSA from a large sample of subjects. After enrichment, the purity of the
fresh and archived HSA specimens were similar, suggesting that the thiol-affinity resin
removed the lower molecular weight contaminants from archived specimens of HSA.
One fresh HSA specimen (sample 1.5 in Figure 5), and two of the pooled archived samples
(one of the duplicates of samples 6 and 9 in Figure 5), were excluded from statistical analysis
due to low volumetric and protein recoveries after treatment with thiol-affinity resins. The
estimated mean adduct level for fresh HSA was 0.076 (SD 0.010) mg adducts/mg HSA after
enrichment. When the amount of HSA-Cys34-IAA positive control (0.047 mg HSA-Cys34-
IAA/mg HSA) was subtracted from this value, the mean adduct level was 0.029 mg adducts/
mg HSA. The estimated mean adduct level in the archived specimens was 0.323 (SD 0.059)
mg adducts/mg HSA, which was much higher than observed in freshly isolated HSA.
We used general linear models to investigate effects of race, gender, and smoking status on
adduct levels in enriched specimens of archived HSA. Race (black vs. white) did not
significantly affect adduct levels (P-value = 0.739) and was dropped from the model. The
model with gender and smoking status explained 42.5% of the observed variation in adduct
levels (i.e., R2 = 0.425) and produced the analysis of variance table shown in Table 2. After
adjustment for gender, nonsmokers had significantly higher adduct levels than smokers (0.349
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vs. 0.289 mg adducts/mg HSA; P-value = 0.0445) and after adjustment for smoking status,
males had higher adduct levels than females, although the difference was not statistically
significant (0.342 vs. 0.296 mg adducts/mg HSA; P-value = 0.1121) Since we expected to
observe higher adduct levels in smoking subjects compared to control subjects, interpretation
of the apparent increase in adduct levels among nonsmokers must await information about the
identities of the particular adducts involved. In any case, these results should be regarded as
very preliminary due to the small numbers of HSA samples in our analyses.
Enriched HSA Adducts as Biomarkers of Exposure
As noted in the introduction, protein adducts can serve as biomarkers of exposure to a host of
xenobiotic toxicants and reactive endogenous species [3;4]. However, because the levels of
protein adducts are small compared to the unmodified proteins, they are difficult to detect and
identify without prior enrichment. By removing mercaptalbumin (i.e., unadducted HSA) with
thiol-affinity resins, we obtained protein fractions consisting largely of HSA molecules that
had been adducted at the HSA-Cys34 locus. Since HSA-Cys34 is the most nucleophilic and one
of the most abundant reaction sites in serum, the method should be useful for characterizing
adducts of important reactive electrophiles in the blood. Since the ultimate goal of our research
is to identify unknown HSA-Cys34 adducts in tryptic digests of fresh and archived specimens
of human plasma, the successful enrichment of such adducts is clearly important.
Based upon measurements of total proteins before and after enrichment of HSA, we observed
about 10 times higher levels of non-disulfide adducts in archived specimens of HSA compared
to fresh HSA (Table 1). This points to the possibility that HSA-Cys34 had been modified during
either isolation or storage (11 y at -80°C), or both. Because archived specimens will often be
used to characterize adduct levels associated with chemical exposures, it is important to
determine the exact nature of modifications to HSA-Cys34 that occur during isolation and
storage.
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(A) LC-MS total ion chromatogram of freshly isolated HSA. The peak labeled HSA represents
the HSA fraction of the plasma proteins after precipitation of immunoglobulins by treatment
of plasma with 60% ammonium sulfate. (B) Raw ESI mass spectrum of the HSA fraction. (The
deconvoluted mass spectrum is shown in Figure 2A.)
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Deconvoluted ESI mass spectra showing heterogeneity of HSA from various sources. (A)
Freshly isolated HSA; (B) commercial HSA, and (C) HSA stored at -80°C for 11 years.
Mercaptalbumin (66,436 Da) is the most abundant species in fresh HSA (A), with minor peaks
at 66,556 Da and 66,599 Da, corresponding to cysteinylation and glycosylation, respectively.
Commercial HSA (B) was the most highly oxidized of the three HSA preparations. The most
abundant modification was from cysteinylated (66,556 Da), with peaks at 66,473 and 66,593
Da consistent with the addition of NO and glucose, respectively. Archived HSA (C) displayed
elevated cysteinylation (66,556 Da) and glycosylation (66,590 Da), and also contained an
unknown abundant modification at 66,496 (+60) Da. The modification at 66,496 Da appears
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to be an irreversible modification at Cys34. The asterisks in (B) denote masses of 66,473 Da
and 66,512 Da. (A representative LC-MS total ion chromatogram for the freshly isolated HSA
sample is provided in Figure 1A. The raw mass spectrum of the HSA peak from the freshly
isolated HSA sample is shown in Figure 1B.)
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Reduction of commercial HSA using TCEP and DTT followed by reaction with IAA.
Deconvoluted ESI mass spectra illustrate (A) optimal conditions using 2.7 molar excess DTT
and (B) more stringent reduction conditions using 270 molar excess DTT. In spectrum A, peaks
at 66,493, 66,599, and 66,654 Da correspond to HSA-Cys34-IAA, HSA-Gluc, and HSA-
Cys34-IAA+Gluc, respectively. The peak at 66,554 Da is thought to represent a pool of
unknown HSA-Cys34 adducts. In spectrum B, the series of ~57 Da mass additions indicate
reduction of intramolecular disulfide linkages, with the addition of 2 IAA molecules
representing a broken disulfide.
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Deconvoluted ESI mass spectra of fresh HSA (A) before and (B) after treatment with thiol-
affinity resins (0.047 mg/mg HSA-Cys34-IAA was added prior to enrichment as a positive
control). In the pre-enrichment sample, (A), peaks were observed at 66,436, 66,556, and 66,599
Da, corresponding to mercaptalbumin, cysteinylated HSA, and glycosylated HSA,
respectively. After enrichment, (B), a peak was observed at 66,493 Da for the HSA-Cys34-
IAA positive control, which was not detected before enrichment. Peaks at 66,545 and 66,705
Da are thought to represent a pool of Cys34 and glycosylated Cys34 adducts, respectively. Note
that no peak corresponding to unmodified HSA was observed after treatment with thiol-affinity
resins.
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SDS-PAGE images of HSA before and after enrichment. Before enrichment (upper panel):
fresh HSA is labeled as ID 1 and pooled archived HSA is labeled with IDs 2 - 9. After
enrichment (lower panel): fresh HSA replicates are labeled with IDs 1.1 - 1.6 and pooled
archived HSA specimens are labeled with IDs 2 - 9.
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